

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/070,439	MURAKAMI ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Thomas McKenzie Ph.D.	1624	

**All Participants:**

(1) Thomas McKenzie Ph.D.

(2) Daniel J. Pereira, Ph.D.

**Status of Application:** \_\_\_\_\_

(3) \_\_\_\_\_

(4) \_\_\_\_\_

**Date of Interview:** 26 February 2004

**Time:** 3:45

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☐ No

If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

*enablement for treating obesity and ketoacidosis*

Claims discussed:

*15 and 24*

Prior art documents discussed:

*Yamauchi (J. Clin. Invest.) and Yamauchi (J. Biol. Chem.)*

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

*See Continuation Sheet*

**Part III.**

- ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

  
 (Examiner/SPE Signature)

\_\_\_\_\_  
 (Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: while the new general use claims would be allowable, the two specific disease treatment claims would lack enablement. Neither document cited by Applicants provides any clinical data would be required to provide the correlation between Applicants' assay and their proposed disease treatments. Such treatment is still speculative.